Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Aroa Soriano Fernández

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca
Aroa Soriano Fernández

Aroa Soriano Fernández

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Projects

A phase I trial of ABTL0812 in paediatric patients with advanced cancer including neuroblastoma

IP: Lucas Moreno Martín-Retortillo
Collaborators: Cristina Gamez Cenzano, Aroa Soriano Fernández, Luis Riera Soler, Miguel Segura Ginard, Carlota Aguilera Ordoñez
Funding agency: Instituto de Salud Carlos III
Funding: 826760.77
Reference: ICI21/00076
Duration: 01/01/2022 - 31/12/2025

Implementation and new biomarker development for Personalised Medicine for Childhood Cancers in Spain

IP: Lucas Moreno Martín-Retortillo
Collaborators: Aroa Soriano Fernández, Marta Garrido Pontnou, Miguel Segura Ginard, Lorena Valero Arrese, Raquel Hladun Alvaro, Elena Antima Martinez Saez, Marta Sese Faustino, Gabriela Guillén Burrieza, Josep Roma Castanyer, Andrea Vilaplana Blanes, Margarita Ortega Blanco, María Rosario Pérez- Torres Lobato, Asbleidy Carolina Torres Barbosa, Berta Campos Estela
Funding agency: Instituto de Salud Carlos III
Funding: 369260
Reference: PMP21/00073
Duration: 01/01/2022 - 31/12/2025

Next generation personalised medicine for childhood cancers

IP: Lucas Moreno Martín-Retortillo
Collaborators: Aroa Soriano Fernández, Jessica Camacho Soriano, Raquel Hladun Alvaro, Gabriela Guillén Burrieza, Andrea Vilaplana Blanes, Lorena Valero Arrese, Mariona Morell Daniel
Funding agency: Instituto de Salud Carlos III
Funding: 214170
Reference: PI21/01661
Duration: 01/01/2022 - 30/06/2026

Quatsomes as a novel nanomaterial platform for nucleic acids delivery

IP: Miguel Segura Ginard
Collaborators: Aroa Soriano Fernández, Lucas Moreno Martín-Retortillo
Funding agency: Instituto de Salud Carlos III
Funding: 83600
Reference: DTS20/00018
Duration: 01/01/2021 - 31/12/2022

Related news

ERN-EuroBloodNet

Vall d'Hebron leads the analysis of COVID-19 in rare hematological diseases

The study analyzes the impact of COVID-19 on people with rare red blood cell disorders, identifying risk factors for severe forms of the disease.

Entrega xec Mi compañero de viaje

Mi Compañero de Viaje adds a decade of donations in the fight against cancer

The association, once again, has shown its commitment to oncological research with a donation of €19,197 to the Cancer and Hematological Diseases Group for Children at VHIR.

Equip del grup de Càncer i Malalties Hematològiques Infantils del VHIR

A study demonstrates the effectiveness of gene therapy in patients with Fanconi anemia

The prestigious journal The Lancet has published the results of this study, which is the result of more than 20 years of pre-clinical research and 7 years of patient follow-up.

See more

Related professionals

Lorena Ramos Pérez

Lorena Ramos Pérez

Research technician
Diabetes and Metabolism
Read more
Maria Pilar Delgado Martínez

Maria Pilar Delgado Martínez

Main researcher
Neurovascular Diseases
Read more
Cristina Berastegui Garcia

Cristina Berastegui Garcia

Main researcher
Pneumology
Read more
Laura Vidal Tarrason

Laura Vidal Tarrason

Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.